Results 141 to 150 of about 163,730 (308)

Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy

Pharmaceutics
Extensive research into mRNA vaccines for cancer therapy in preclinical and clinical trials has prepared the ground for the quick development of immune-specific mRNA vaccines during the COVID-19 pandemic.
Theodora Katopodi, Savvas Petanidis, Eirini Grigoriadou, Doxakis Anestakis, Charalampos Charalampidis, Ioanna Chatziprodromidou, George Floros, Panagiotis Eskitzis, Paul Zarogoulidis, Charilaos Koulouris, Christina Sevva, Konstantinos Papadopoulos, Panagiota Roulia, Stylianos Mantalovas, Marios Dagher, Alexandros Vasileios Karakousis, Nikolaos Varsamis, Konstantinos Vlassopoulos, Vasiliki Theodorou, Chrysi Maria Mystakidou, Nikolaos Iason Katsios, Konstantinos Farmakis, Christoforos Kosmidis   +22 more
doaj   +1 more source

From Chatbots to Co‐Scientists: The Impact of Knowledge‐Generating AI (AI 4.0) on Healthcare and Research

Advanced Science, EarlyView.
This perspective contrasts the historical, linear progression of early AI with the dynamic, iterative nature of AI 4.0; and it describes the real‐world medical applications and the necessary evolution of laboratory infrastructure brought about by AI 4.0.
Weida Liu, Gary Peltz
wiley   +1 more source

A novel adjuvant Ling Zhi-8 for cancer DNA vaccines

, 2014
DNA vaccines have a wide range of applications, with several potential advantages compared with other vaccine technologies for diseases. No DNA vaccine has yet been licensed in humans; however, a lot of effort has been made to enhance their potential as ...
Chen, Dz-Chi, Lin, Chi-Chen, Chu, Ching-Liang   +2 more
core   +1 more source

Toward Predictable Nanomedicine: Current Forecasting Frameworks for Nanoparticle–Biology Interactions

Advanced Intelligent Discovery, EarlyView.
Predictive models successfully screen nanoparticles for toxicity and cellular uptake. Yet, complex biological dynamics and sparse, nonstandardized data limit their accuracy. The field urgently needs integrated artificial intelligence/machine learning, systems biology, and open‐access data protocols to bridge the gap between materials science and safe ...
Mariya L. Ivanova, Michael Nicholls, Nicola Russo, Gueorgui Mihaylov, Konstantin Nikolic   +4 more
wiley   +1 more source

Therapeutic vaccines and cancer: focus on DPX-0907

, 2014
Mohan Karkada,1,2 Neil L Berinstein,3 Marc Mansour1 1ImmunoVaccine Inc, 2Department of Microbiology/Immunology, Dalhousie University, Halifax, NS, Canada; 3Ontario Institute for Cancer Research, Toronto, ON, Canada Abstract: In an attempt to ...
Berinstein NL, Mansour M, Karkada M
core  

Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy

Cancer vaccines represent a promising approach within immunotherapies. These vaccines are tailored to target tumor-specific antigens, thereby offering a precision approach to cancer treatment.
Jani, Chinmay T, Marijo Bilusic, Aysswarya Manoharan, DeMaria, Peter J, Chinmay T. Jani, Manoharan, Aysswarya, Bilusic, Marijo, Peter J. DeMaria   +7 more
core   +1 more source

VLPs and particle strategies for cancer vaccines

, 2013
Effective delivery of tumor antigens to APCs is one of the key steps for eliciting a strong and durable immune response to tumors. Several cancer vaccines have been evaluated in clinical trials, based on soluble peptides, but results have not been fully ...
UNGARO, FRANCESCA, Fabiana Quaglia, Maria Lina Tornesello, Claudia Conte, Franco M. Buonaguro, Franco M Buonaguro, QUAGLIA, FABIANA, Luigi Buonaguro, Francesca Ungaro, CONTE, CLAUDIA   +9 more
core   +1 more source

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Development of a loop‐mediated isothermal amplification‐lateral flow dipstick (LAMP‐LFD) assay and on‐site rapid detection evaluation for Rodentibacter heylii and Rodentibacter pneumotropicus

Animal Models and Experimental Medicine, EarlyView.
This study established a closed‐tube LAMP‐LFD assay for detecting Rodentibacter heylii and Rodentibacter pneumotropicus. The method exhibited high sensitivity (detection limits of 10−5 ng/μL for R. heylii and 10−4 ng/μL for R. pneumotropicus), high specificity, reliable performance with clinical samples, and effective validation in experimental ...
Huiqiong Yan, Sisi Chen, Yuhan Gan, Jing Xing, Yufang Feng, Xin Wen, Jie Fang, Jiangtao Du, Shasang Zhou, Honggang Guo, Xiaoyin Jin, Zhiyuan Wang, Junhao Tao, Lingqun Lu, Qingming Kong, Huazhong Ying, Wei Han, Fangwei Dai   +17 more
wiley   +1 more source

Chemically Regulated STING‐Activating Prodrugs of Deoxyribose Cyclic Dinucleotides Elicit Robust Immune Activation and Durable Antitumor Immunity

Angewandte Chemie, EarlyView.
All three diastereoisomers of an esterase‐sensitive phosphotriester dCDN prodrug demonstrate improved activity. The (Rp,Rp) diastereoisomer shows the highest activity with an EC50 of 1.7 nM in STING activation and displays the most pronounced antitumor activity via intravenous administration, significantly suppressing tumor proliferation, extending the
Zhiqiang Xie, Huimin Liu, Yuchen Yang, Xiaohan Sun, Jingwen Wang, Tianxiang Liu, Baifan Wang, Wenrui Qiu, Yiwen Sun, Yuting Bai, Yao Zhang, Dejun Ma, Rong Xiang, Shibo Li, Zhen Xi   +14 more
wiley   +2 more sources